Botanical species · safety record

Tridax procumbens

The EFSA Compendium of Botanicals holds 13 constituent measurements for Tridax procumbens. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Tridax procumbens (L.) L.

13Constituent measurements
0Safety records
6Cited sources
0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

  • Alkaloids4
  • Saponins3
  • Pyrrolizidine alkaloids2
  • Bergenin1
  • Esculetin1
  • Tannic acid1
  • Tannins1

Plant parts

  • Leaves6
  • Aerial part of plants4
  • Live plants2
  • Flowering top1

Preparations

  • Solvent extraction10

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
EsculetinLive plantsSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI
AlkaloidsAerial part of plantsSolvent extraction≥ 0.38 PercentPhytochemical screeningNo resolvable identifier
AlkaloidsAerial part of plantsSolvent extraction≤ 0.78 PercentPhytochemical screeningNo resolvable identifier
AlkaloidsLeavesPhytochemical screeningNo resolvable identifier
AlkaloidsLeavesSolvent extraction29.1828 Milligram/kilogramGC-FIDNo resolvable identifier
BergeninLive plantsSolvent extractionColorimetry, Spectroscopy (Spectrometry) and PhotometryNo resolvable identifier
Pyrrolizidine alkaloidsFlowering topSolvent extractionStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier
Pyrrolizidine alkaloidsLeavesSolvent extractionStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier
SaponinsAerial part of plantsSolvent extraction≥ 1.69 PercentPhytochemical screeningNo resolvable identifier
SaponinsAerial part of plantsSolvent extraction≤ 1.71 PercentPhytochemical screeningNo resolvable identifier
SaponinsLeaves103.52 Milligram/100 gramPhytochemical screeningNo resolvable identifier
Tannic acidLeavesSolvent extraction5294.78 Milligram/kilogramGC-FIDNo resolvable identifier
TanninsLeaves4.72 Milligram/100 gramPhytochemical screeningNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. C. Ikewuchi, J., C. Ikewuchi, C., M. Igboh, N. Chemical profile of Tridax procumbens Linn. Pakistan journal of nutrition, 2009, vol. 8, no. 5, p. 548-550.
  2. Edeoga, HO., Okwu, DE., Mbaebie, BO. Phytochemical constituents of some Nigerian medicinal plants. AFRICAN JOURNAL OF BIOTECHNOLOGY, 2005, vol. 4, no. 7, p. 685-688.
  3. Ikewuchi, Jude Chigozie. ALTERATION OF PLASMA BIOCHEMICAL, HAEMATOLOGICAL AND OCULAR OXIDATIVE INDICES OF ALLOXAN INDUCED DIABETIC RATS BY AQUEOUS EXTRACT OF TRIDAX PROCUMBENS LINN (ASTERACEAE) . Excli journal, 2012, vol. 11, p. 291-308.
  4. Akbar, E., Malik, A., Afza, N., Hai, SMA. Flavone glycosides and bergenin derivatives from Tridax procumbens. Heterocycles, 2002, vol. 57, no. 4, p. 733-+.
  5. Xu, Runsheng., Zhang, Jing., Yuan, Ke. Two New Flavones from Tridax procumbens Linn. Molecules, 2010, vol. 15, no. 9, p. 6357-6364. DOI
  6. Kone, Witabouna Mamidou., Kande, Brahima. Qualitative analysis of the pyrrolizidine alkaloids from 11 Asteraceae and Boraginaceae used in traditional medicine in Cote d'Ivoire. Research journal of phytochemistry, 2012, p. 75-83.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue